6.750SEK+1.20%Mkt Cap: 3.13B SEKP/E: —Last update: 2026-05-13
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for t…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)56.42
PEG—
P/B7.90
P/S49.55
EV/EBITDA-7.45
EV/Revenue41.33
EPS (TTM)-0.90
EPS (Forward)0.12
Cash Flow & Leverage
FCF Yield-4.06%
FCF Margin-201.23%
Operating CF-267.00M SEK
CapEx (TTM)1.50M SEK
Net Debt/EBITDA0.19
Net Debt-67.30M SEK
Technical
SMA 505.746 (+17.5%)
SMA 2005.365 (+25.8%)
Beta0.76
S&P 52W Chg24.23%
Avg Vol (30d)907.84K
Avg Vol (10d)899.70K
Technical Indicators
RSI (14)69.4
MACD0.3040
MACD Signal0.2309
MACD Hist.+0.0731
BB Upper6.968 SEK
BB Middle6.013 SEK
BB Lower5.058 SEK
BB Width31.75%
ATR (14)0.3231 SEK
Vol Ratio (20d)0.49x
52W Range
3.02592% of range7.070
52W High7.070 SEK
52W Low3.025 SEK
Profitability
Gross Margin19.87%
EBITDA Margin0.00%
Profit Margin-548.88%
Oper. Margin-693.28%
ROE-101.15%
ROA-53.59%
Revenue Growth5.50%
Earnings Growth—
Balance Sheet
Debt/Equity0.27
Current Ratio0.69
Quick Ratio0.65
Book Value/Sh0.8570 SEK
Cash/Share0.3610 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.461.83M
Float247.80M
Insiders23.38%
Institutions34.19%
Analyst Consensus
Rating2.3 (Buy)
Target (Mean)8.775 SEK
Target Range1.600 SEK – 12.00 SEK
# Analysts4
Company
Market Cap3.13B SEK
Enterprise Value2.61B SEK
Revenue (TTM)63.10M SEK
Gross Profit12.40M SEK
Net Income (TTM)-342.50M SEK
Revenue/Share0.1670 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees44
Last Price6.750 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—